A Non-Interventional Post-Market Clinical Follow-up Study of Patients Transfused with Blood Components Treated with the INTERCEPT Blood System in Routine Therapeutic Use (HV6) First published 20/01/2023 Last updated 14/03/2024 EU PAS number:EUPAS49030 Study Ongoing